What the FDA labels say about taking them together
Clorazepate and cobicistat, elvitegravir, emtricitabine and tenofovir alafenamide
Cobicistat, elvitegravir, emtricitabine and tenofovir alafenamide's FDA label of February 3, 2025 names clorazepate in its drug interactions section; the clorazepate label PlainMeds reads does not name cobicistat, elvitegravir, emtricitabine and tenofovir alafenamide. The cobicistat, elvitegravir, emtricitabine and tenofovir alafenamide label: “Triazolam and orally administered midazolam are extensively metabolized by CYP3A. Coadministration of triazolam or orally administered midazolam with GENVOYA may cause large increases in the concentrations of these …”
Check it at the source: the clorazepate FDA label on DailyMed (effective September 10, 2026, Apotex Corp.); the cobicistat, elvitegravir, emtricitabine and tenofovir alafenamide FDA label on DailyMed (effective February 3, 2025, Gilead Sciences, Inc.).
What does the clorazepate label say about cobicistat, elvitegravir, emtricitabine and tenofovir alafenamide?
Clorazepate's label (effective September 10, 2026) does not name cobicistat, elvitegravir, emtricitabine and tenofovir alafenamide in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Clorazepate Dipotassium), ANDA215566 (Corepharma), as published by Apotex Corp., effective September 10, 2026 (SPL set 6e07efe5-29b6-6d1e-661a-f696c4b17f43), via openFDA; the full label on DailyMed
What does the cobicistat, elvitegravir, emtricitabine and tenofovir alafenamide label say about clorazepate?
Cobicistat, elvitegravir, emtricitabine and tenofovir alafenamide label, drug interactionsConcomitant Drug Class/Drug Name: Other benzodiazepines: e.g., parenterally administered midazolam clorazepate diazepam estazolam flurazepam; Effect on Concentration ↑ = Increase, ↓ = Decrease: ↑ sedatives/hypnotics; Clinical Comment: Triazolam and orally administered midazolam are extensively metabolized by CYP3A. Coadministration of triazolam or orally administered midazolam with GENVOYA may cause large increases in the concentrations of these benzodiazepines. Coadministration of parenteral midazolam with GENVOYA should be done in a setting that ensures close clinical monitoring and appropriate medical management in case of respiratory depression and/or prolonged sedation. …
Source: FDA drug label (Genvoya), Gilead Sciences, Inc., effective February 3, 2025 (SPL set 34784acf-15ed-4715-b504-eb30430518e9), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Clorazepate | Cobicistat, elvitegravir, emtricitabine and tenofovir alafenamide | |
|---|---|---|
| Labeled for | Anxiety, Seizures and epilepsy | HIV |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | $0.524 per tablet 3.75 mg tablet | $143.35 per tablet Genvoya tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once